Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$5 Mln
P/E Ratio
--
P/B Ratio
0.32
Industry P/E
--
Debt to Equity
--
ROE
-0.73 %
ROCE
-187.82 %
Div. Yield
0 %
Book Value
14782.68
EPS
-13904.58
CFO
$--
EBITDA
$--
Net Profit
$--
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Pasithea Therapeutics Corp (KTTA)
| -46.35 | 28.03 | -32.94 | -76.66 | -58.24 | -- | -- |
|
BSE Sensex*
| 2.78 | 3.89 | 5.96 | 9.08 | 11.82 | 20.15 | 11.37 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Pasithea Therapeutics Corp (KTTA)
| -97.80 | 1,053.19 | -63.73 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.44 | 10,315.11 | 21.27 | 23.13 | |
| 298.18 | 8,705.27 | 22.77 | 66.44 | |
| 27.46 | 10,589.59 | -- | -28.77 | |
| 106.46 | 10,559.67 | 32.44 | 14.16 |
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a... next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. Address: 1111 Lincoln Road, Miami Beach, FL, United States, 33139 Read more
Co-Founder, MD & Executive Chairman
Dr. Lawrence Steinman BA, M.D., Ph.D.
Co-Founder, MD & Executive Chairman
Dr. Lawrence Steinman BA, M.D., Ph.D.
Headquarters
Miami Beach, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Pasithea Therapeutics Corp (KTTA) stood at $ 16,065 Mln as on 31-Dec-24
The share price of Pasithea Therapeutics Corp (KTTA) is $1.69 (NASDAQ) as of 28-Apr-2025 16:02 EDT. Pasithea Therapeutics Corp (KTTA) has given a return of -58.24% in the last 3 years.
Pasithea Therapeutics Corp (KTTA) has a market capitalisation of $ 5 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Pasithea Therapeutics Corp (KTTA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Pasithea Therapeutics Corp (KTTA) and enter the required number of quantities and click on buy to purchase the shares of Pasithea Therapeutics Corp (KTTA).
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. Address: 1111 Lincoln Road, Miami Beach, FL, United States, 33139
The CEO & director of Dr. Lawrence Steinman BA, M.D., Ph.D.. is Pasithea Therapeutics Corp (KTTA), and CFO & Sr. VP is Dr. Lawrence Steinman BA, M.D., Ph.D..
There is no promoter pledging in Pasithea Therapeutics Corp (KTTA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Pasithea Therapeutics Corp (KTTA) | Ratios |
|---|---|
|
Return on equity(%)
|
-187.82
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Pasithea Therapeutics Corp (KTTA) was $0 Mln.
$-0.04
(
